Following the release of the company's first-quarter earnings results, shares of MannKind (NASDAQ:MNKD), a commercial stage biopharma focused on inhaled drug delivery, fell 20% Thursday.
Here's a look at the key financial highlights from the first quarter:
- Revenue was $3 million. That figure included $1.8 million in bulk sales to a third party and $1.2 million in revenue from Afrezza sales to patients.
- Deferred revenue was $1.8 million at the end of the quarter.
- MannKind posted a net loss for the quarter of $16.3 million, or $0.17 per share. By contrast, Wall Street was expecting a net loss of only $0.09.
- Despite posting the big net loss, MannKind's cash balance rose from $22 million at the end of December to $48 million at the end of March. The increase was due to a $30.6 million payment from Sanofi, a $16.7 million gain on the sale of its Valencia Property, and $2.1 million in payments from Afrezza shipments.
- $30.1 million remains available for borrowing from the Mann Group.
- The company's monthly cash burn rate dropped to $7.4 million from $10.3 million in the year-ago period.
Traders reacted harshly to news of a higher-than-expected net loss.
Here's what MannKind's CEO Matt Pfeffer had to say on the investor call about the company's financial situation: "The cash we have today should take us comfortably into the third quarter, but we estimate to get to the end of the year will probably take us another $20 million to $30 million beyond that. That said, I have no doubt and I'm quite confident we will have no difficulty raising that money to get us to where we need to be."
Pfeffer also mentioned that MannKind has been primarily focused on raising capital through the use of debt instruments because "we've not been very happy with the stock price."
MannKind's quarterly results once again show that this company is in a tough position. It's attempting to simultaneously cut its costs and build out its commercial capabilities. That's no small task.
Meanwhile, today's plunge brings the company's share price closer to once again dropping below the $1 mark. The last time that happened for an extended period of time, the Nasdaq threatened to delist the company's stock, which Pfeffer had previously stated would be "disastrous for the company on many levels." To remain compliant, the company decided to execute a reverse stock split, but that decision didn't sit well with shareholders.
The best that MannKind shareholders can hope for from here is that either Afrezza sales seriously accelerate in the next quarter or the company accepts a buyout offer. Will either situation materialize? No one knows for sure, but I certainly have my doubts.
More from The Motley Fool
The Simple Reason Why I Won't Buy MannKind Corporation Stock
MannKind isn't a turnaround story worth buying.
These Two Updates Caused MannKind's Stock to Plunge 25.9% in December
The hits keep on coming for the biotech.
Why MannKind Corporation Jumped Higher Today
Afrezza prescriptions are headed in the right direction.